CollaGenex Pharmaceuticals' New Drug Application for ORACEA Accepted for Review by FDA
3rd Oct 2005, 17:43 GMT
CollaGenex Pharmaceuticals announced that the New Drug Application for Oracea, the 1st orally administered, systemically delivered drug developed to treat rosacea, has been accepted for review by the US FDA.
CollaGenex Pharmaceuticals' New Drug Application for ORACEA Accepted for Review by FDA related news:
- Market Pulse: CollaGenex: FDA to review application for rosacea treatment — Pharmaceuticals News from StratCenter.com
- FDA will consider CollaGenex skin drug — Latest news from Philadelphia Business Journal
- CollaGenex Stock Up on Oracea Application — Financial News News from StratCenter.com
- FDA to review CollaGenex rosacea treatment — Pharmaceutical Business Review Online
- Valeant's Parkinson's drug still not approved by FDA — Pharmaceutical Business Review Online
- FDA clears Innovive compound for human trials — Pharmaceutical Business Review Online
- Market Pulse: Celgene says action date on Revlimid NDA delayed 3 months — Pharmaceuticals News from StratCenter.com
- Lannett Company Receives Approval for Danazol — Pharmaceuticals News from StratCenter.com
- Celgene Delayed on Revlimid OK by FDA — Pharmaceuticals News from StratCenter.com
- FDA Allows INNOVIVE Pharmaceuticals' IND for INNO-105 to Treat Advanced Solid Malignancies — Rednova News - Health
Latest news from Financial News News from StratCenter.com:
- TRADE NEWS: Agilent Technologies Introduces High-Speed, High-Volume USB Multifunction Data Acquisition Modules, Chassis
- Bio-Rad Closes Buy of Ciphergen Unit
- The LGL Group Reports Q3 Earnings
- Analogic CEO to retire
- Analogic CEO Plans to Retire
- Meade Instruments Contracts with Leading Asian Outsource Manufacturing Firm
- JMAR Receives Nasdaq Delisting Notice
- Analogic Corp Announces Mgmt Changes
- Bio-Rad Purchases Life Science Research Business From Ciphergen Biosystems
- Agilent to buy Switzerland's Acqiris